Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Daily News

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

L.A. McKeown

December 11, 2017

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day One

Shelley Wood

October 30, 2017

Presentation ESC 2017

Guidelines for the Management of Acute Myocardial Infarction in Patients presenting with ST-Segment Elevation

Presenter: Borja Ibanez

August 28, 2017

News Conference News ESC 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

Shelley Wood

August 27, 2017

Presentation ESC 2017

Bivalirudin vs Heparin Monotherapy in Myocardial Infarction:The VALIDATE-SWEDEHEART Trial

Presenter: David Erlinge

August 27, 2017

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

News Daily News

Ad Hoc PCI Safe and Feasible in Patients Undergoing TAVR

Leah Lawrence

August 10, 2017

News Industry News

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

July 25, 2017

News Daily News

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

Shelley Wood

July 21, 2017

News Industry News

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

May 25, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

News Daily News

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Michael O'Riordan

February 03, 2017

Advertisement

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Live From Denver: TCT 2017, Day One

Guidelines for the Management of Acute Myocardial Infarction in Patients presenting with ST-Segment Elevation

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

Bivalirudin vs Heparin Monotherapy in Myocardial Infarction:The VALIDATE-SWEDEHEART Trial

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Ad Hoc PCI Safe and Feasible in Patients Undergoing TAVR

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content